These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20720215)

  • 1. Are herbal medicines ripe for the cancer clinic?
    Eng C
    Sci Transl Med; 2010 Aug; 2(45):45ps41. PubMed ID: 20720215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.
    Lam W; Bussom S; Guan F; Jiang Z; Zhang W; Gullen EA; Liu SH; Cheng YC
    Sci Transl Med; 2010 Aug; 2(45):45ra59. PubMed ID: 20720216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
    Lam W; Jiang Z; Guan F; Hu R; Liu SH; Chu E; Cheng YC
    BMC Complement Altern Med; 2014 Dec; 14():490. PubMed ID: 25510341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
    Schoemaker NE; Kuppens IE; Huinink WW; Lefebvre P; Beijnen JH; Assadourian S; Sanderink GJ; Schellens JH
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):263-70. PubMed ID: 15592838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
    Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
    Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan and UFT/leucovorin in patients with advanced cancers.
    Stevenson JP; Redlinger M; Sun W; Haller D; O'Dwyer PJ
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):91-2. PubMed ID: 11098504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing irinotecan-associated diarrhea in children.
    Wagner LM; Crews KR; Stewart CF; Rodriguez-Galindo C; McNall-Knapp RY; Albritton K; Pappo AS; Furman WL
    Pediatr Blood Cancer; 2008 Feb; 50(2):201-7. PubMed ID: 17570704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
    Innocenti F; Undevia SD; Ramírez J; Mani S; Schilsky RL; Vogelzang NJ; Prado M; Ratain MJ
    Clin Pharmacol Ther; 2004 Nov; 76(5):490-502. PubMed ID: 15536463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
    Kramar A; Gourgou-Bourgade S; Ychou M
    J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
    [No Abstract]   [Full Text] [Related]  

  • 10. [New cancer therapies: balancing risk and benefit].
    Rothenberg ML
    Gan To Kagaku Ryoho; 1998 May; 25(6):797-9. PubMed ID: 9617315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal toxicity or irinotecan.
    Hecht JR
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):72-8. PubMed ID: 9726096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A1 genotyping in patients undergoing treatment with irinotecan.
    Innocenti F
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):843-4. PubMed ID: 16491625
    [No Abstract]   [Full Text] [Related]  

  • 13. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
    Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN
    Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062
    [No Abstract]   [Full Text] [Related]  

  • 14. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan (Campto) in the treatment of pancreatic cancer.
    Pizzolato JF; Saltz LB
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
    Dy GK; Mandrekar S; Peethambaram PP; Okuno SH; Croghan GC; Hanson LJ; Furth A; Adjei AA
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):623-8. PubMed ID: 15999272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan for metastatic colorectal cancer.
    Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 19. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
    Nikolic-Tomasevic Z; Jelic S; Popov I; Radosavljevic D
    J Chemother; 2000 Jun; 12(3):244-51. PubMed ID: 10877521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
    Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
    Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.